FDA accepts reduced sample size for X4’s 4WARD Phase 3
X4 Pharmaceuticals said the FDA agreed to reduce 4WARD Phase 3 to 126 patients, accepted the proposed safety database, and the company targets enrollment completion by year-end 2026.
X4 Pharmaceuticals said the FDA agreed to reduce the sample size for its 4WARD Phase 3 study to 126 and to accept the proposed safety database, while targeting enrollment completion by year-end 2026. Original SEC Filing: X4 Pharmaceuticals, Inc. [XFOR] - 8-K - Sep. 08, 2026.